Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Funck-Brentano

Showing results (11-20 of 112) with videos related to

Pageof 12
Sort By:
Revue D'Epidemiologie Et De Sante Publique|February 16, 2000
[Survival analysis example based on an event history model from a clinical trial in cardiology]R Lancar, C Funck-Brentano
Therapie|February 10, 2000
[How can institutional structures make clinical research in France more operational?]C Funck-Brentano, R Brouard
The American Journal of Cardiology|January 15, 1988
Overview of the clinical pharmacology of antiarrhythmic drugsR L Woosley, C Funck-Brentano
Archives Des Maladies Du Coeur Et Des Vaisseaux|February 1, 1991
[Pertinence of animal and human models in the evaluation of ventricular anti-arrhythmia agents]C Funck-Brentano, J Y Le Heuzey
Fundamental & Clinical Pharmacology|May 5, 1999
Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokineticsL Becquemont, C Funck-Brentano, P Jaillon
European Heart Journal|August 1, 1987
Exercise test: arrhythmogenic or antiarrhythmic? Rate-dependency vs. adrenergic-dependency of tachyarrhythmiasP Coumel, M Zimmermann, C Funck-Brentano
British Heart Journal|May 1, 1987
Neurogenic hypertension associated with an excessively high excretion rate of catecholamine metabolitesC Funck-Brentano, J Y Pagny, J Menard
Gastroenterologie Clinique Et Biologique|April 1, 1983
[Hepatitis caused by various derivatives of erythromycin]C Funck-Brentano, D Pessayre, J P Benhamou
British Heart Journal|June 1, 1986
Reversible renal failure after combined treatment with enalapril and frusemide in a patient with congestive heart failureC Funck-Brentano, G Chatellier, J M Alexandre
British Heart Journal|November 1, 1986
The authors replyC Funck-Brentano, G Chatellier, J M Alexandre
Pageof 12

Showing results (11-20 of 112) with videos related to

Sort By:
Pageof 12
Revue D'Epidemiologie Et De Sante Publique|February 16, 2000
[Survival analysis example based on an event history model from a clinical trial in cardiology]R Lancar, C Funck-Brentano
Therapie|February 10, 2000
[How can institutional structures make clinical research in France more operational?]C Funck-Brentano, R Brouard
The American Journal of Cardiology|January 15, 1988
Overview of the clinical pharmacology of antiarrhythmic drugsR L Woosley, C Funck-Brentano
Archives Des Maladies Du Coeur Et Des Vaisseaux|February 1, 1991
[Pertinence of animal and human models in the evaluation of ventricular anti-arrhythmia agents]C Funck-Brentano, J Y Le Heuzey
Fundamental & Clinical Pharmacology|May 5, 1999
Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokineticsL Becquemont, C Funck-Brentano, P Jaillon
European Heart Journal|August 1, 1987
Exercise test: arrhythmogenic or antiarrhythmic? Rate-dependency vs. adrenergic-dependency of tachyarrhythmiasP Coumel, M Zimmermann, C Funck-Brentano
British Heart Journal|May 1, 1987
Neurogenic hypertension associated with an excessively high excretion rate of catecholamine metabolitesC Funck-Brentano, J Y Pagny, J Menard
Gastroenterologie Clinique Et Biologique|April 1, 1983
[Hepatitis caused by various derivatives of erythromycin]C Funck-Brentano, D Pessayre, J P Benhamou
British Heart Journal|June 1, 1986
Reversible renal failure after combined treatment with enalapril and frusemide in a patient with congestive heart failureC Funck-Brentano, G Chatellier, J M Alexandre
British Heart Journal|November 1, 1986
The authors replyC Funck-Brentano, G Chatellier, J M Alexandre
Pageof 12